The supplementary dossiers for the renewal of the approval of the active substances Aureobasidium pullulans (strains DSM 14940 and DSM 14941), Bacillus amyloliquefaciens subsp. plantarum D747, benalaxyl-M, imazamox, Pseudomonas sp. strain DSMZ 13134, pyriofenone and pyroxsulam were submitted via the central submission system on 28 January 2022, 31 March 2022, 27 April 2022, 31 January 2022, 28 January 2022, 27 January 2022 and 30 April 2022 respectively, and the rapporteur Member States are still in the process of assessing the admissibility of the applications for the renewal of the approval of each of those active substances. As a consequence, the risk assessment pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 has not yet been finalised by the respective rapporteur Member States and additional time is required to complete the remaining steps in each renewal procedure. The applications for the renewal of the approval of the active substances Bacillus amyloliquefaciens subsp. plantarum D747, imazamox, pyriofenone and pyroxsulam have been made public by the Authority pursuant to Article 10 of Implementing Regulation (EU) 2020/1740.
Recital 27, Regulation (EU) 2025/99
In forcesince 21 Jan 2025